Calistoga Pharmaceuticals, Inc.

Five big investments in health care and life science funds since the end of October delivered more than $1bn in new financing for companies developing biopharmaceuticals and related technology. The ne

Cancer specialist TG Therapeutics Inc. has recently shown positive mid-stage data for its assets, both alone and in combination, in patients with advanced B-cell cancers. The speed with which it b

Two and a half years after Calistoga Pharmaceuticals was acquired by Gilead Sciences for up to $600m, Frazier Healthcare finally lured Calistoga's former CEO Carol Gallagher to help the venture capita

The wide-open IPO window has given private companies more liquidity options, so maybe it’s no wonder that pharmas are willing to pay more than usual for closely held start-ups. Judging by some recent